Linc

Linc EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Linc (LINC.ST) as of Nov 20, 2026 is -422.82 M SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 1.28 B SEK — a change of -133.11% (lower).

EBITDA

-422.82 MSEK

YoY

-133.11%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Linc is 2025 -422.82 M SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Linc was 2024 1.28 B SEK. It decreases by -133.11% lower compared to the previous year.

The Linc EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
304.15 M SEK
Jan 1, 2019
602.24 M SEK
Jan 1, 2020
970.05 M SEK
Jan 1, 2021
-37.14 M SEK
Jan 1, 2022
-898.43 M SEK
Jan 1, 2023
648.65 M SEK
Jan 1, 2024
1.28 B SEK
Jan 1, 2025
-422.82 M SEK
The Linc EBITDA history
YEAREBITDAYoY
-422.82 MSEK-133.11%
1.28 BSEK+96.87%
648.65 MSEK-172.20%
-898.43 MSEK+2,318.83%
-37.14 MSEK-103.83%
970.05 MSEK+61.07%
602.24 MSEK+98.01%
304.15 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Linc is -422.82 M SEK in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Linc changed from 1.28 B SEK to -422.82 M SEK, representing a -133.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Linc since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Linc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Linc

All Key Metrics — Linc